WW International, Inc. (Weight Watchers) announced that it is now offering access to Eli Lilly and Company's newly FDA-approved oral GLP-1, Foundayo (orforglipron) through its Med+ offering and affiliated medical groups. The addition gives members a new once-daily, injection-free option for adults with obesity or overweight with weight-related medical problems and further expands the company's growing portfolio of FDA-approved oral GLP-1 treatments, all within a clinically supported program designed to help them succeed. Through Weight Watchers Med+, clinically eligible members will be able to access this newly approved medication alongside care from board-certified clinicians, insurance support, and additional tools designed to support the treatment journey.
All Med+ members also receive direct access to the Weight Watchers GLP-1 Success program to support them before, during, and after medication use. For members choosing self-pay, pricing will start at $149 per month for the lowest dose, with pricing varying by dose. Weight Watchers Med+ enables access, if appropriate, to medications like Foundayo with an integrated support model designed to help members navigate treatment in real life.
Among Med+ members prescribed a GLP-1, those who regularly engaged with the GLP-1 Success Program for 12 months lost 29.1% more body weight, on average, than those who did not engage in behavioral support.
